Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy at the Congress of the European Society of Cardiology (ESC) in London earlier this month. In July, TiGenix acquired the smaller biotech CoreTherapix with the AlloCSC-01 pipeline. This stem-cell therapy is for regeneration of heart muscle following a heart attack, and is currently undergoing its phase II trial ‘CAREMI’.
TiGenix NV, from Leuven (Belgium) recently bought out Madrid-based CoreTherapix, a former subsidiary of Spanish biotech Genetrix for a contractual total of €267M. This is a hefty sum for a small biotech only founded in 2008, for sure. However, it is the excitement surrounding Coretherapix’s cardiac stem cell therapy AlloCSC-01 which has sparked a euromillion rush.
AlloCSC-01 is designed as a reparative tool to treat patients who have experienced an acute myocardial infarction (AMI) in order to reduce ischemic damage. Phase I results have been overwhelmingly positive, with AlloCSC-01 demonstrating a comprehensive safety profile (announced at the ESC). Since over 1.5 million AMIs occur annually across the US and EU,